Protein kinase Cα deletion causes hypotension and decreased vascular contractility

Brandi M Wynne1,2, Cameron G McCarthy3, Theodora Szasz3

  • 1Renal Division, Department of Medicine.

Journal of Hypertension
|November 10, 2017
PubMed
Abstract

Insights

Global deficiency of Protein Kinase C alpha (PKCα) reduces mean arterial pressure (MAP) by decreasing vascular contractility. This study utilized PKCα knockout mice to investigate the role of PKCα in blood pressure regulation.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Biology
  • Renal Physiology

Background:

  • Protein Kinase C alpha (PKCα) regulates cell signaling pathways, vascular contractility, and ion transport.
  • The specific role of PKCα in modulating mean arterial pressure (MAP) has not been previously investigated.

Purpose of the Study:

  • To investigate the role of PKCα in the regulation of MAP using a whole-animal PKCα knockout (PKC KO) model.
  • To test the hypothesis that global PKCα deficiency reduces MAP through decreased vascular contractility.

Main Methods:

  • Ambulatory blood pressure was measured in PKC KO and control mice under normal and high-salt diets using radiotelemetry.
  • Metabolic cage studies assessed urinary sodium excretion.
  • Vascular reactivity studies were performed on aorta and mesenteric arteries.

Main Results:

  • PKC KO mice exhibited significantly lower diastolic, systolic, and MAP compared to controls, irrespective of diet.
  • No significant differences in urinary sodium excretion were observed between groups.
  • PKC KO mice showed reduced vascular relaxation and maximal contraction in aorta and mesenteric arteries.

Conclusions:

  • Global deletion of PKCα leads to reduced MAP.
  • This reduction in MAP is attributed to decreased vascular contractility in the absence of altered sodium excretion.

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
570
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.3K
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
1.8K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.3K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.6K